KRYS News and Press, Krystal Biotech Inc. From 02/28/22

Following successful completion of GEM-3 pivotal trial, Krystal is on track to file BLA for Vyjuvek™ for the treatment of dystrophic epidermolysis bullosa in 1H 2022; MAA filing anticipated in 2H 2022 Phase 1 trial of KB407 in cystic fibrosis patients in Australia expe...

PITTSBURGH, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat at Cowen’s 42 n...

Krystal produced excellent phase 3 data. It has major competitive advantages over peers. The company is flush with cash. For further details see: Krystal Biotech: The Future Looks More And More Derisked

Investing in small-cap, clinical-stage biotech stocks can be a double-edged sword. While shares of these companies can skyrocket following positive clinical or regulatory news, they can just as quickly lose a substantial amount of their value in a short period if things don't go their way. ...

PITTSBURGH, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare disease, announced today the appointments of Jing Marantz as Chief Business Officer and Rand Sutherland as a new me...

Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have been added to Goldman Sach's Healthcare Strategic Asse...

The biotechnology industry is an excellent place to start for those looking for stocks with explosive growth potential. Shares of biotech companies can quickly skyrocket following positive business-related news. In addition, considering the demand for innovative life-saving drugs only to pi...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks closed out the week with a decline, but managed to limit some damage with last-hour buying. The Nasdaq (COMP.IND) -1.9% took the brunt...

On Nov 29, KRYS reported positive topline results from their pivotal phase 3 trial of "VYJUVEK™ in Patients with Dystrophic Epidermolysis Bullosa (DEB). Pivotal GEM-3 trial met its primary and secondary endpoints, i.e. the differences in complete wound healings between treatmen...

Krystal Biotech (NASDAQ: KRYS) saw its shares climb more than 77% this week, according to data provided by S&P Global Market Intelligence . The stock was only at $39.81 at Friday's close, then opened at $91.20 on Monday and climbed to as high as $102.99. While the stock has ...